Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
New England Journal of Medicine · 31.08.2023 · 389 (9) · 783-794
DOI: 10.1056/nejmoa2216455 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 31.08.2023. Verfasst von Tadashi Matsushita und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Transfusion Medicine, Nagoya University Hospital, Nagoya (T.M.), and Nara Medical University, Kashiwara (K.N.) - both in Japan…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hemophilia A, Thromboembolism. Die Arbeit wurde bisher 153-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
BACKGROUND: Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration. A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors. METHODS: We conducted the explorer7 trial to assess the safety and efficacy of concizumab in patients with hemophilia A or B with inhibitors. Patients were randomly assigned in a 1:2 ratio to receive no prophylaxis for at least 24 weeks (group 1) or concizumab prophylaxis for at least 32 weeks (group 2) or were nonrandomly assigned to receive concizumab prophylaxis for at least 24 weeks (groups 3 and 4). After a treatment pause due to nonfatal thromboembolic events in three patients receiving concizumab, including one from the explorer7 trial, concizumab therapy was restarted with a loading dose of 1.0 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily (potentially adjusted on the basis of concizumab plasma concentration as measured at week 4). The primary end-point analysis compared treated spontaneous and traumatic bleeding episodes in group 1 and group 2. Safety, patient-reported outcomes, and pharmacokinetics and pharmacodynamics were also assessed. RESULTS: Of 133 enrolled patients, 19 were randomly assigned to group 1 and 33 to group 2; the remaining 81 were assigned to groups 3 and 4. The estimated mean annualized bleeding rate in group 1 was 11.8 episodes (95% confidence interval [CI], 7.0 to 19.9), as compared with 1.7 episodes (95% CI, 1.0 to 2.9) in group 2 (rate ratio, 0.14 [95% CI, 0.07 to 0.29]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Transfusion Medicine, Nagoya University Hospital, Nagoya (T.M.), and Nara Medical University, Kashiwara (K.N.) - both in Japan; Indiana Hemophilia and Thrombosis Center, Indianapolis (A.S.); the D…
ORCID-Profile: Tadashi Matsushita
Förderung
- Novo Nordisk
Zitieren
APA
Matsushita, T., Shapiro, A., Abraham, A., Angchaisuksiri, P., Castaman, G., Cepo, K., d'Oiron, R., Frei-Jones, M., Goh, A. S., Haaning, J., Hald Jacobsen, S., Mahlangu, J., Mathias, M., Nogami, K., Skovgaard Rasmussen, J., Stasyshyn, O., Tran, H., Vilchevska, K., Villarreal Martinez, L., …, & explorer7 Investigators (2023). Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. New England Journal of Medicine, 389(9), 783-794. https://doi.org/10.1056/nejmoa2216455
Vancouver
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. New England Journal of Medicine. 2023;389(9):783-794. doi:10.1056/nejmoa2216455
BibTeX
@article{Matsushita2023,
author = {Matsushita, Tadashi and Shapiro, Amy and Abraham, Aby and Angchaisuksiri, Pantep and Castaman, Giancarlo and Cepo, Katarina and d'Oiron, Roseline and Frei-Jones, Melissa and Goh, Ai-Sim and Haaning, Jesper and Hald Jacobsen, Sanja and Mahlangu, Johnny and Mathias, Mary and Nogami, Keiji and Skovgaard Rasmussen, Josephine and Stasyshyn, Oleksandra and Tran, Huyen and Vilchevska, Kateryna and Villarreal Martinez, Laura and Windyga, Jerzy and You, Chur Woo and Zozulya, Nadezhda and Zulfikar, Bulent and Jiménez-Yuste, Victor and explorer7 Investigators, explorer7 Investigators},
title = {Phase 3 Trial of Concizumab in Hemophilia with Inhibitors},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {9},
pages = {783--794},
doi = {10.1056/nejmoa2216455}
}
EUVIMED